← All trials

NCT04565990

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jan 22, 2021
Primary completion
Dec 31, 2025
Completion date
Aug 25, 2028
First posted
Sep 28, 2020
Last posted
Dec 22, 2020
Enrollment
50
Arms / groups
1 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.